Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D07KDI
|
|||
Former ID |
DNCL002558
|
|||
Drug Name |
AR-42
|
|||
Synonyms |
AR-42; 935881-37-1; OSU-HDAC42; AR 42; (S)-HDAC-42; (S)-N-Hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide; UNII-E0GG29V0AQ; (S)-HDAC 42; E0GG29V0AQ; AR42; HDAC-42; AR-42 (HDAC-42); N-hydroxy-4-{[(2S)-3-methyl-2-phenylbutanoyl]amino}benzamide; N-hydroxy-4-[[(2S)-3-methyl-2-phenylbutanoyl]amino]benzamide; AR-42 (OSU-HDAC42); AC1OCFYN; cc-20; OSU-HDAC 42; MLS006011089; CHEMBL191482; SCHEMBL2348844; OSU-42; DTXSID4042678; NOCAS_42678; CTK8C1969; AOB3995; N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide; MolPort-009-019-571
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 1/2 | [1] | |
Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Phase 1/2 | [1] | ||
Company |
Arno Therapeutics
|
|||
Structure |
Download2D MOL |
|||
Formula |
C18H20N2O3
|
|||
Canonical SMILES |
CC(C)C(C1=CC=CC=C1)C(=O)NC2=CC=C(C=C2)C(=O)NO
|
|||
InChI |
1S/C18H20N2O3/c1-12(2)16(13-6-4-3-5-7-13)18(22)19-15-10-8-14(9-11-15)17(21)20-23/h3-12,16,23H,1-2H3,(H,19,22)(H,20,21)/t16-/m0/s1
|
|||
InChIKey |
LAMIXXKAWNLXOC-INIZCTEOSA-N
|
|||
CAS Number |
CAS 935881-37-1
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
12015940, 16365153, 17195136, 43530211, 56311875, 56311876, 56311877, 76386780, 103459967, 104058086, 114788655, 121502280, 124360784, 125164697, 136340193, 137275997, 144115620, 152258503, 160647338, 160835020, 162011371, 162037396, 162202755, 163096883, 163400712, 163642943, 163780962, 163845631, 163893779, 164193982, 164779936, 174007070, 174531570, 175608083, 184823753, 198970418, 204429377, 223573464, 223705142, 228467178, 244301594, 252109885, 252450625, 252457354
|
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of Arno Therapeutics. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.